Thursday, April 24, 2014
Publication and contact
Patient studies suggest
IL-15 could be useful for treating colorectal cancer. In a cohort of patients
with colorectal cancer, carriers of an IL-15 deletion had lower IL-15
expression and showed lower levels of B and T cell proliferation in the tumor
microenvironment than patients without the deletion. Carriers of the IL-15
deletion also showed increased risk of tumor recurrence and decreased
survival. Next steps include developing mouse models to evaluate the
therapeutic use of IL-15 alone and in combination with checkpoint inhibitors.
Altor BioScience Corp. has ALT-803,
an IL-15-mutant agonist complexed to an Fc fusion protein of IL-15
in Phase I testing to treat melanoma and preclinical development for other
Pharma S.A.S. has CYP0150,
a fusion protein of IL-15 and IL-15RA, in preclinical development for cancer
cancer with IL-15 page 7).
Published online April 24, 2014
Patent application filed
covering gene signature for cancer prognosis and tumor classification that
includes IL-15; available for licensing and partnering
Mlecnik, B. et al. Sci.
Transl. Med.; published online March 19, 2014;
Contact: Jérôme Galon, Institut National de la Santé et de
la Recherche Médicale (INSERM), Paris, France
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]